Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Conditions
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions
e-Device
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Conditions
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

ALL Adult Consortium Trial: Adult ALL Trial

NCT00476190
Conditions
Acute Lymphoblastic Leukemia
Interventions
Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Conditions
Hepatitis B
Interventions
Telbivudine (LdT), peginterferon alpha-2a
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, dexamethasone, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
Conditions
Retinoblastoma
Interventions
vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation
Drug · Other · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 365 Days
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Completed Phase 4 Interventional Results available

Envarsus in Delayed Graft Function (E-DGF)

NCT03864926
Conditions
Delayed Graft Function
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability Study of an Edible Colon Preparation

NCT02402270
Conditions
Bowel Preparation
Interventions
NuLYTELY® (PEG 3350), ECP-019, MoviPrep® (PEG 3350)
Drug
Lead sponsor
ColonaryConcepts LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana • Lebanon, New Hampshire
Conditions
Primary Mediastinal Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Conditions
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
711
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
Conditions
T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
prednisone, vincristine sulfate, daunorubicin hydrochloride, asparaginase, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, leucovorin calcium, dexamethasone, doxorubicin hydrochloride, thioguanine, radiation therapy, nelarabine, pegaspargase, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Completed Phase 1 Interventional Accepts healthy volunteers

Studying Different Formulations of SR13668 in Healthy Volunteers

NCT00896207
Conditions
Healthy, no Evidence of Disease
Interventions
Akt inhibitor SR13668
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 62 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
213
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
Topotecan, dexamethasone, vincristine, E. coli Asparaginase, PEG-L-asparaginase, erwinia asparaginase, fludarabine, methotrexate, mercaptopurine, idarubicin, etoposide, cytarbine, teniposide, chemotherapy, intrathecal chemotherapy, steroid therapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
ProAgio, FOLFIRI, Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy, Calaspargase Pegol-mknl, Cobimetinib
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Conditions
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
Interventions
Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
Conditions
Solid Cancers
Interventions
Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more